{
    "clinical_study": {
        "@rank": "21810", 
        "acronym": "NIAGARA", 
        "arm_group": [
            {
                "arm_group_label": "Salivary equivalent", 
                "arm_group_type": "Experimental", 
                "description": "Single dose stick without any active substance"
            }, 
            {
                "arm_group_label": "Aequasyal", 
                "arm_group_type": "Sham Comparator", 
                "description": "Multidose moisturizing oral spray without any active substance"
            }, 
            {
                "arm_group_label": "Biotene", 
                "arm_group_type": "Sham Comparator", 
                "description": "Multidose moisturizing oral spray without any active substance"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the clinical efficacy, safety and acceptability of\n      our new oral salivary equivalent in the relief of signs and symptoms related to mouth\n      dryness as compared to two distinct moisturizing currently marketed oral sprays (Aequasyal\u00ae\n      & Biotene\u00ae) in patients with xerostomia due to chronic hyposalivation."
        }, 
        "brief_title": "A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Xerostomia", 
            "Hyposalivation", 
            "Head and Neck Cancer", 
            "Sj\u00f6gren Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Xerostomia", 
                "Sjogren's Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "National, multicentre, randomised, active controlled, crossover, open-label study using a\n      3-latin-square design.\n\n      200 evaluable patients have been recruited"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients:\n\n          -  Aged 18 years or more,\n\n          -  Clinical diagnosis of xerostomia by a severe reduction of salivation, as detected by\n             patient's answers to few specific questions and measured by saliva volume at\n             screening visit (test of saliva weight absorbed \u2264 0.1g/min)\n\n          -  Any medical condition or treatment leading to a severe reduction of salivation\n             related to either:\n\n          -  Head and neck radiation therapy for cancer,\n\n          -  Gougerot-Sj\u00f6gren syndrome\n\n          -  Medications known to induce xerostomia (psychotropic drugs, antihypertensive drugs)\n\n          -  Dehydration, hypothyroidism, Parkinson's disease and/or diabetes mellitus\n\n          -  Female patients must be post-menopausal or using a highly effective method for\n             avoidance of pregnancy throughout the whole study duration, if childbearing\n             potential.\n\n          -  Able to understand and comply with the protocol procedures\n\n          -  Willing and able to give their written informed consent\n\n          -  Affiliated to the French National Health Insurance Program\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to one of the study products or to one of their components\n\n          -  Any planned change in dosing of all known medications inducing mouth dryness\n\n          -  Concomitant treatment for xerostomia symptoms without a scheduled 3 to 7-day\n             withdrawal window\n\n          -  Oral candidiasis as diagnosed by a microbiological test obtained from an unstimulated\n             whole saliva sample until 3-week period from disease release\n\n          -  Oral ulceration\n\n          -  Alcohol (>2 glasses of wine/day), smoking (>10 cigarettes/day), caffeine and/or\n             theine intake (>4 cups/day)\n\n          -  Patients unable to fill out the questionnaires or to comply with the study protocol\n\n          -  Dental infection\n\n          -  Patients participating to another clinical trial at the time of the study entry or\n             within 30 days prior to study enrolment\n\n          -  Life-threatening condition at the time of the study\n\n          -  Pregnant or lactating women and women of childbearing potential refusing to use\n             adequate contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02049112", 
            "org_study_id": "UN/2011/001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Salivary equivalent", 
                "description": "14-day treatment with salivary equivalent sticks", 
                "intervention_name": "Salivary equivalent", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Aequasyal", 
                "description": "14-day treatment with Aequasyal oral spray", 
                "intervention_name": "Aequasyal", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Biotene", 
                "description": "14-day treatment with Biotene oral spray", 
                "intervention_name": "Biotene", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cross-over", 
            "Salivary equivalent", 
            "Dry mouth", 
            "Medical device"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Magnanville", 
                    "country": "France", 
                    "zip": "78200"
                }, 
                "name": "Leopold Bellan Private Hospital"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 4 Study Evaluating Efficacy, Safety and Acceptability of Treatment With a New Salivary Equivalent Compared to Two Moisturizing Mouth Sprays on the Improvement of Dry Mouth Symptoms and Oral Comfort in Patients With Xerostomia.", 
        "overall_official": {
            "affiliation": "Leopold Bellan Fundation", 
            "last_name": "Michel SALOM, Medical", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patient evaluation through the completion of a self rated 100 mm long VAS score. Anchor points of the VAS score will be 0 representing the absence of any dry mouth symptoms and 100 representing the worst imaginable picture of dry mouth discomfort", 
            "measure": "Dry mouth discomfort", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02049112"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patient evaluation through the completion of a self rated 100 mm long VAS score.", 
                "measure": "Mouth burning sensation", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Patient evaluation through the completion of a self rated 100 mm long VAS score.", 
                "measure": "Speech difficulties", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Patient evaluation through the completion of a self rated 100 mm long VAS score.", 
                "measure": "Chewing difficulties", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Patient evaluation through the completion of a self rated 100 mm long VAS score.", 
                "measure": "Swallowing difficulties", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Patient evaluation through the completion of a self rated 100 mm long VAS score.", 
                "measure": "Taste perversion", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Patient evaluation through the completion of a self rated 100 mm long VAS score.", 
                "measure": "Medical device acceptability", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Patient evaluation through the completion of a self rated 100 mm long VAS score.", 
                "measure": "Medical device safety assessment", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Unither Pharmaceuticals, France", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Unither Pharmaceuticals, France", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}